NewsSymbiotec Pharmalab IPO Day 4: Issue subscribed 18.36x so far. Check issue details and key datesSymbiotec Pharmalab IPO Day 4: Issue subscribed 18.36x so far. Check issue details and key dates
- Symbiotec Pharmalab IPO closed with an overall subscription of 18.36x.
- QIB category surged 2696% intra-day on Day 4, ending at 17.62x.
- NII (bHNI) was the most subscribed category at 54.66x.
- Allotment is scheduled for August 28, 2026.
- Shares are set to list on September 1, 2026.
*this image is generated using AI for illustrative purposes only.
Symbiotec Pharmalab’s IPO witnessed a dramatic late-stage surge on Day 4, with Qualified Institutional Buyers (QIB) jumping 2696% intra-day. The overall subscription closed at 18.36x, with the Non-Institutional Individual (NII) category leading demand at up to 54.66x. Retail interest moderated slightly to 6.47x.
Final Subscription Status
The issue ended its final day with significant momentum from institutional investors who accelerated bids in the afternoon session. The NII (bHNI) segment continued to dominate individual investor demand.
| Category | Subscription Multiple |
|---|---|
| QIB | 17.62x |
| NII (bHNI) | 54.66x |
| NII (sHNI) | 32.34x |
| Retail | 6.47x |
| Employees | 6.56x |
| Overall | 18.36x |
Subscription Progression
Demand accelerated sharply throughout the four-day window. While early days saw modest interest, Day 4 brought a decisive institutional push that lifted the total multiple significantly.
| Day | Date | QIB | NII (bHNI) | NII (sHNI) | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 | 24-08-2026 | 0.35x | 1.56x | 0.77x | 0.94x | 0.79x |
| Day 2 | 25-08-2026 | 0.54x | 4.03x | 2.42x | 2.08x | 1.83x |
| Day 3 | 26-08-2026 | 0.59x | 13.77x | 11.11x | 5.00x | 5.24x |
| Day 4 | 27-08-2026 | 17.62x | 32.34x | 54.66x | 6.47x | 18.36x |
Intra-day Timeline (27-08-2026)
The standout move occurred between 11:15 AM and 2:15 PM, where QIB subscription raced ahead, more than tripling again in the final hours.
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.63x | 23.10x | 6.76x | 9.17x |
| 12:15 | 2.01x | 28.88x | 8.07x | 12.07x |
| 13:15 | 10.40x | 35.50x | 9.18x | 17.19x |
| 14:15 | 17.62x | 32.34x | 6.47x | 18.36x |
About the Company
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company. It holds a global leadership position in corticosteroid and steroidal-hormone APIs, with a 38.2% global volume market share in corticosteroids. Founded in 2002, the company operates as a CDMO for specialty pharmaceutical companies globally.
Financial Highlights
The company reported consistent revenue growth over the last three fiscal years. Total equity increased significantly, reflecting retained earnings and capital efficiency.
| Particulars | FY 2026 (₹ crores) | FY 2025 (₹ crores) | FY 2024 (₹ crores) |
|---|---|---|---|
| Revenue from Operations | 869.15 | 751.55 | 716.25 |
| Total Profit (PAT) | 109.90 | 96.79 | 100.06 |
| Total Equity | 1149.59 | 814.71 | 714.84 |
Objects of the Issue
- Prepayment and/or repayment of outstanding borrowings: ₹112.50 crores
- General corporate purposes: Balance net proceeds
Risk Factors
- High Revenue Concentration in APIs: 96.07% of revenue derived from API sales in Fiscal 2026.
- Regulatory Compliance Risks: Manufacturing facilities subject to inspections; recent US FDA Form 483 observations noted.
- Significant Export Revenue Exposure: 67.04% of revenue from external customers outside India in Fiscal 2026.
What's Next
- Allotment Date: 2026-08-28
- Listing Date: 2026-09-01
- Basis of Allotment: Pro-rata basis expected given high subscription multiples in NII and Retail categories.
How might the recent US FDA Form 483 observations impact Symbiotec's post-listing valuation and long-term export stability to the US market?
Given the heavy reliance on API sales (96% of revenue), how vulnerable is the company to potential price volatility or supply chain disruptions in the corticosteroid sector?
Will the repayment of ₹112.50 crores in outstanding borrowings significantly improve the company's debt-to-equity ratio and interest coverage in the coming fiscal years?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
